Consensus ORIC Pharmaceuticals, Inc.

Stocks

ORIC

US68622P1093

Biotechnology & Medical Research

Real-time Estimate Cboe BZX 12:13:16 06/10/2026 am IST			5-day change	1st Jan Change
12.40 ^USD	+1.64%		-6.25%	+52.08%

15/09	ORIC Pharmaceuticals, Inc. Presents at Morgan Stanley 24th Annual Global Healthcare Conference, Sep-15-2026 10:00 AM
29/08	Oric Pharmaceuticals Insider Sold Shares Worth $1,053,814, According to a Recent SEC Filing	MT

Evolution of the Average Target: ORIC Pharmaceuticals, Inc.

Evolution of the Target Price: ORIC Pharmaceuticals, Inc.

Changes in Analyst Recommendations: ORIC Pharmaceuticals, Inc.

b25ab28f00549de0.D687nhHm9JQy4Z96-tiq8tuy2Uwb3yv_CORqjFZTfaw.POsD5F2LjaFGudsVyJbaha_egyJEu2CHQqkz1BsbD91pgmnHR7ST4wWY_A~6ff147e74cf7910595228db113aab8f5

Analysts' recommendations: ORIC Pharmaceuticals, Inc.

04:41pm	Leerink Partners Initiates ORIC Pharmaceuticals at Outperform With $26 Price Target	MT
23/09	BTIG Initiates ORIC Pharmaceuticals at Buy With $26 Price Target	MT
01/04	Wedbush Cuts Price Target on ORIC Pharmaceuticals to $17 From $20, Keeps Outperform Rating	MT
07/01	Piper Sandler Initiates ORIC Pharmaceuticals Inc at Overweight With $22 Price Target	MT
14/11	Oppenheimer Adjusts Price Target on ORIC Pharmaceuticals to $15 From $12, Maintains Outperform Rating	MT
06/25/06	Oppenheimer Adjusts Price Target on ORIC Pharmaceuticals to $12 From $15, Maintains Outperform Rating	MT
31/24/31	JonesTrading Initiates ORIC Pharmaceuticals at Buy With $17 Price Target	MT
31/24/31	Wells Fargo Initiates ORIC Pharmaceuticals at Overweight With $20 Price Target	MT
06/24/06	Stifel Nicolaus Initiates Coverage on ORIC Pharmaceuticals With Buy Rating, $20 Price Target	MT
13/24/13	Oppenheimer Adjusts ORIC Pharmaceuticals Price Target to $15 From $17, Maintains Outperform Rating	MT
27/24/27	JPMorgan Trims ORIC Pharmaceuticals' Price Target to $18 From $19, Maintains Overweight Rating	MT
21/24/21	HC Wainwright Adjusts ORIC Pharmaceuticals' Price Target to $21 From $15, Keeps Buy Rating	MT
12/24/12	Baird Cuts Price Target on ORIC Pharmaceuticals to $25 From $27, Maintains Outperform Rating	MT
01/24/01	Wedbush Adjusts Oric Pharmaceuticals' Price Target to $20 From $12, Maintains Outperform Rating	MT
26/24/26	Cantor Fitzgerald Initiates ORIC Pharmaceuticals at Overweight Rating	MT
13/23/13	HC Wainwright Trims Price Target on ORIC Pharmaceuticals to $15 From $16, Keeps Buy Rating	MT
12/23/12	Wedbush Lowers ORIC Pharmaceuticals' PT to $12 From $14, Pushes Out Launch Assumption for ORIC-533; Keeps Outperform Rating	MT
26/23/26	HC Wainwright Adjusts Price Target on ORIC Pharmaceuticals to $16 From $13, Maintains Buy Rating	MT
24/23/24	JPMorgan Adjusts ORIC Pharmaceuticals' Price Target to $17 From $14, Maintains Overweight Rating	MT
23/23/23	Citigroup Adjusts ORIC Pharmaceuticals' Price Target to $15 From $13, Maintains Buy Rating	MT
22/23/22	Wedbush Starts ORIC Pharmaceuticals at Outperform With $14 PT, Says Expanding Pipeline Provides Future Potential Growth Opportunities	MT
16/23/16	Baird Adjusts Price Target on ORIC Pharmaceuticals to $27 From $15, Keeps Outperform Rating	MT
15/23/15	HC Wainwright Adjusts Price Target on ORIC Pharmaceuticals to $13 From $14, Keeps Buy Rating	MT
10/23/10	HC Wainwright Adjusts Price Target on ORIC Pharmaceuticals to $14 From $16, Keeps Buy Rating	MT
05/23/05	Citigroup Adjusts Price Target on ORIC Pharmaceuticals to $8 From $9, Maintains Buy Rating	MT

More recommendations

Bio Therapeutic Drugs

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	ORIC PHARMACEUTICALS, INC.					+72.69%
	WUXI APPTEC CO., LTD.					+11.79%
	ARGENX SE					+27.75%
	LONZA GROUP AG					+21.67%
	REVOLUTION MEDICINES, INC.					+24.6%
	IQVIA HOLDINGS INC.					+11.82%
	BEONE MEDICINES AG					+21.07%
	CELLTRION, INC.					+46.63%
	WUXI BIOLOGICS (CAYMAN) INC.					+6.77%
	BIONTECH SE					+20.91%
	Average					+26.57%
	Weighted average by Cap.					+20.90%